Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Exelixis, Inc. < Previous 1 2 3 4 Next > Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine September 16, 2024 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024 September 15, 2024 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September August 28, 2024 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update August 06, 2024 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors August 06, 2024 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024 July 23, 2024 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Present at the William Blair 44th Annual Growth Stock Conference May 28, 2024 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA May 20, 2024 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May May 07, 2024 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update April 30, 2024 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024 April 16, 2024 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March February 27, 2024 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update February 06, 2024 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February February 01, 2024 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024 January 25, 2024 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024 January 23, 2024 From Exelixis, Inc. Via Business Wire Tickers EXEL European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets January 18, 2024 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024 January 07, 2024 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024 January 02, 2024 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023 December 07, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer December 04, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023 November 21, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023 November 10, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update November 01, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023 October 22, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023 October 18, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor September 12, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors August 24, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer August 23, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer August 21, 2023 From Exelixis, Inc. Via Business Wire Tickers EXEL < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.